Quick Answer
Alaunos Therapeutics, Inc. reported Research And Development Expense of $1.36 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +276.5% in Research And Development Expense from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2009 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: $24.64 million | Q3 2011: $10.67 million | Q1 2012: $13.99 million | Q2 2012: $18.26 million | Q3 2012: $16.22 million | Q1 2013: $19.11 million | Q2 2013: $14.78 million | Q3 2013: $6.25 million | Q1 2014: $6.54 million | Q2 2014: $8.35 million | Q3 2014: $9.73 million | Q1 2015: $74.25 million | Q2 2015: $7.42 million | Q3 2015: $16.97 million | Q1 2016: $10.20 million | Q2 2016: $129.23 million | Q3 2016: $8.98 million | Q1 2017: $11.97 million | Q2 2017: $10.83 million | Q3 2017: $11.11 million | Q1 2018: $10.18 million | Q2 2018: $7.49 million | Q3 2018: $8.26 million | Q1 2019: $9.48 million | Q2 2019: $10.00 million | Q3 2019: $8.64 million | Q1 2020: $12.71 million | Q2 2020: $12.05 million | Q3 2020: $13.97 million | Q1 2021: $13.34 million | Q2 2021: $13.57 million | Q3 2021: $14.52 million | Q1 2022: $5.58 million | Q2 2022: $5.94 million | Q3 2022: $7.89 million | Q1 2023: $6.50 million | Q2 2023: $5.19 million | Q3 2023: $3.66 million | Q1 2024: $126.0 thousand | Q2 2024: $180.0 thousand | Q3 2024: $143.0 thousand | Q1 2025: $347.0 thousand | Q2 2025: $185.0 thousand | Q3 2025: $469.0 thousand.
- Over the full 18 years of available data (2009 to 2025), Alaunos Therapeutics, Inc.'s Research And Development Expense has declined by 70.1%.
- Historical annual values: Fiscal year 2025: $1.36 million | Fiscal year 2024: $362.0 thousand | Fiscal year 2023: $16.28 million | Fiscal year 2022: $25.02 million | Fiscal year 2021: $49.64 million | Fiscal year 2020: $52.70 million | Fiscal year 2019: $38.33 million | Fiscal year 2018: $34.13 million | Fiscal year 2017: $45.08 million | Fiscal year 2016: $157.79 million | Fiscal year 2015: $106.79 million | Fiscal year 2014: $32.71 million | Fiscal year 2013: $42.85 million | Fiscal year 2012: $83.45 million | Fiscal year 2011: $57.08 million | Fiscal year 2010: $17.50 million | Fiscal year 2010: $12.91 million | Fiscal year 2009: $4.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: